MMP Capital closed its inaugural asset-backed securitization (ABS) transaction. The offering, MMP Capital 2025A, issued $192 million in notes backed primarily by loans secured by medical aesthetic equipment contracts.
Demand from the institutional investment community exceeded all expectations. The notes drew thirty-five orders from twenty-seven unique investors, and at final pricing were nine times oversubscribed. The senior tranche of the deal earned a Moody’s rating of Aa3.
“MMP Capital 2025A’s overwhelming reception underscores the trust and confidence investors have in our business, our differentiated value proposition for customers and partners and our disciplined approach to risk,” John-Paul M. Smolenski, CEO of MMP Capital, said. “This inaugural ABS marks a pivotal milestone in our strategy to expand our existing business and explore new asset classes.”
The securitization marks the company’s entry into the public capital markets, providing additional liquidity to expand its financing offerings and reach more customers in established and emerging verticals.
